How long has semaglutide been around? The molecule dates to the early 2010s and FDA approval came in December 2017. Here's the full timeline for the drug.
Semaglutide has been around since the early 2010s as a laboratory compound, and it has been FDA-approved for human use in the United States since December 2017, when it reached the market as the type 2 diabetes drug Ozempic. That gives it more than seven years of approved clinical use and roughly a decade of published research behind it. Semaglutide is not a new or experimental medication, even though it only became a household name during the weight-loss boom of 2022 to 2024.
Semaglutide's Timeline at a Glance
The fastest way to answer the question is with dates. Every milestone below represents a real scientific or regulatory step, not a marketing claim.
| Year | Milestone |
|---|---|
| 1980s | Researchers identify and characterize GLP-1, the gut hormone semaglutide mimics. |
| 2005 | Exenatide (Byetta) becomes the first GLP-1 receptor agonist approved in the US. |
| 2010 | Liraglutide (Victoza) is approved for type 2 diabetes. |
| Early 2010s | Semaglutide is first described in the scientific literature as a longer-acting GLP-1 analog. |
| 2016–2017 | Results from the phase 3 SUSTAIN trial program are published. |
| December 2017 | The FDA approves Ozempic, an injectable semaglutide, for type 2 diabetes. |
| September 2019 | Rybelsus becomes the first oral GLP-1 pill approved in the United States. |
| June 2021 | Wegovy is approved for chronic weight management. |
| 2023 | The SELECT trial reports a 20% reduction in major cardiovascular events. |
| March 2024 | Wegovy is approved to reduce cardiovascular risk in adults with overweight or obesity. |
| February 2025 | The FDA declares the semaglutide shortage resolved, ending most large-scale compounding. |
From GLP-1 Discovery to Three Approved Brands
Semaglutide did not appear out of nowhere. It belongs to the GLP-1 receptor agonist family, and that class of drugs has been in clinical use since 2005. Understanding the earlier compounds explains how semaglutide moved from idea to pharmacy shelf so efficiently.
The early GLP-1 drugs
- 1980s: Scientists identify glucagon-like peptide-1, a hormone released by the gut after eating that influences insulin release and appetite.
- 2005: Exenatide (Byetta), derived from Gila monster saliva, becomes the first GLP-1 drug approved in the US.
- 2010: Liraglutide (Victoza) arrives with once-daily dosing for type 2 diabetes.
- 2014: Saxenda, a higher-dose form of liraglutide, is approved for weight management.
Semaglutide was built on that foundation. Chemists modified the GLP-1 molecule with a fatty acid side chain that lets it bind to albumin in the bloodstream, which slows its breakdown and allows once-weekly dosing instead of daily injections.
Semaglutide's own approvals
- December 2017: Ozempic is approved as a once-weekly injection for type 2 diabetes.
- September 2019: Rybelsus becomes the first oral GLP-1 pill approved in the US.
- June 2021: Wegovy is approved for chronic weight management in adults with obesity or with overweight plus a related health condition.
- March 2024: Wegovy gains an added approval to reduce cardiovascular risk, based on the 2023 SELECT trial.
Why Semaglutide Feels Newer Than It Is
A drug that has been on the market since 2017 can still feel brand new. Three factors explain the gap between the approval dates and today's cultural moment.
- Label expansion: Semaglutide only became a weight-loss drug in 2021, and a heart-protective drug in 2024.
- Social media and telehealth: Viral posts and direct-to-consumer platforms pushed demand far beyond the diabetes market.
- Compounded versions: During the shortage, compounding pharmacies produced copycat semaglutide, which made an established molecule look like a brand-new trend.
The FDA declared the semaglutide shortage resolved in February 2025, and large-scale compounding was phased out afterward. That change moved most users back to brand-name products that have gone through full FDA review.
Semaglutide vs. Tirzepatide: Very Different Timelines
Anyone comparing GLP-1 drugs should know that how long has tirzepatide been around is a much shorter story. Tirzepatide is a dual GIP and GLP-1 agonist, and it arrived several years after semaglutide.
| Medication | Active ingredient | First FDA approval | Time on the US market (as of 2025) |
|---|---|---|---|
| Victoza | Liraglutide | January 2010 | About 15 years |
| Ozempic | Semaglutide | December 2017 | More than 7 years |
| Wegovy | Semaglutide | June 2021 | About 4 years |
| Mounjaro | Tirzepatide | May 2022 | About 3 years |
| Zepbound | Tirzepatide | November 2023 | About 2 years |
A longer market history generally means more post-marketing safety data. Semaglutide holds that advantage over tirzepatide, while tirzepatide continues to build its own evidence base through large clinical trials.
Does Semaglutide's Long Track Record Make It Safer?
More than seven years of approval and two decades of GLP-1 research give regulators a substantial safety database. Semaglutide's most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation.
If you are asking how long do semaglutide side effects last, most people find that they ease within a few weeks of starting or increasing a dose. If you want to know how long after semaglutide injection do side effects start, they typically appear within 24 to 72 hours of the shot and feel strongest around day one or two.
Semaglutide is not risk-free. It carries a boxed warning about thyroid C-cell tumors observed in rodents, and it is not recommended for people with a personal or family history of medullary thyroid cancer or MEN2 syndrome. A healthcare professional should review your history before you start any GLP-1 medication.
What Semaglutide's History Means for Users Today
Semaglutide has a half-life of about one week, which is why it is dosed weekly. That slow clearance also answers how long does semaglutide stay in your system: roughly five weeks after the last injection before the drug is essentially gone.
People who handle peptides at home, including anyone who previously used compounded semaglutide, often ask how long is bac water good for. Bacteriostatic water is generally considered usable for about 28 days after the first puncture when stored correctly, and it should be discarded after that window.
The bottom line is that semaglutide is an established, heavily studied medication with a history stretching back to the early 2010s and FDA approval dating to December 2017. Its popularity is recent; its science is not.
Frequently Asked Questions
When did semaglutide first come out?
Semaglutide was first described in the scientific literature in the early 2010s, and the FDA approved the first brand-name version, Ozempic, in December 2017 for type 2 diabetes. Oral semaglutide followed as Rybelsus in September 2019, and Wegovy was approved for weight management in June 2021. The molecule has been available by prescription in the US for more than seven years.
How long has semaglutide been used for weight loss?
Semaglutide has been FDA-approved specifically for weight management since June 2021, when Wegovy launched. Before that, some clinicians prescribed Ozempic off-label for weight loss, but that use was never formally reviewed or approved. In March 2024, Wegovy also received approval to reduce cardiovascular risk in adults with overweight or obesity and existing heart disease.
Is semaglutide considered a new drug?
No. Semaglutide is an established medication with more than seven years of FDA approval and roughly a decade of published clinical research behind it. What is genuinely new is its popularity, which surged after 2021 when the weight-loss version reached the market and social media coverage exploded. Newer GLP-1 options such as tirzepatide have much shorter track records.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.